BFC
PDLI

Blue Fin Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Blue Fin Capital’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-27,371
Closed -$138K – 130
2015
Q3 		$138K Hold
27,371
– – 0.11% 124
2015
Q2 		$176K Sell
27,371
-14,450
-35% -$96.8K 0.13% 134
2015
Q1 		$294K Sell
41,821
-3,000
-7% -$21.7K 0.21% 113
2014
Q4 		$346K Sell
44,821
-2,570
-5% -$20.3K 0.26% 95
2014
Q3 		$354K Buy
47,391
+1,030
+2% +$9.56K 0.28% 93
2014
Q2 		$449K Buy
46,361
+22,805
+97% +$203K 0.36% 82
2014
Q1 		$196K Buy
23,556
+585
+3% +$5.01K 0.17% 119
2013
Q4 		$194K Buy
+22,971
New +$194K 0.17% 116

Other funds holding PDLI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Blue Fin Capital's PDLI Position: Q4 2015 in Review

Blue Fin Capital sold out of PDL BioPharma, Inc. (PDLI) in Q4 2015, closing a stake of 27,371 shares — an estimated $138K sold.

Blue Fin Capital first reported a position in PDLI in Q4 2013 and held it in 8 quarters. The position peaked at $449K in Q2 2014. 204 funds tracked by Wall St. Rank hold PDLI as of Q4 2015.

  • Blue Fin Capital reported no remaining PDL BioPharma, Inc. position as of Q4 2015 after selling out during the quarter.
  • Blue Fin Capital sold 27,371 PDL BioPharma, Inc. shares in Q4 2015, an estimated $138K.
  • Blue Fin Capital first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 8 quarters.
  • Blue Fin Capital's PDL BioPharma, Inc. position peaked at $449K in Q2 2014.
  • 204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2015.

Based on Blue Fin Capital's 13F filing for Q4 2015, filed 7 Jan 2016.